Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
Year: 2016
Type: article
Study design: Observational Study
Abstract: // Marzia Del Re 1 , Marcello Tiseo 2 , Paola Bordi 2 , Armida D’Incecco 3 , Andrea Camerini 4 , Iacopo Petrini 5 , Maurizio Lucchesi 6 , Alessandro Inno 7 , Daniele Spada 8 , Enrico Vasile 6 , Valentina Citi 1 , Giorgio Malpeli 9 , Enrica Testa 8 , Stefania Gori 7 , Alfredo Falcone 6 , Domenico Amoroso 4 , Antonio Chella 10 , Federico Cappuzzo 3 , Andrea Ardizzoni 2 , Aldo Scarpa 9 , Romano Danesi 1 1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 2 Medical Oncology Unit, Azienda Ospedaliero-Universitaria, Parma, Italy 3 Medical Oncology Unit, AUSL6, Istituto Toscano Tumori, Livorno, Italy 4 Medical Oncology Unit, AUSL12, Istituto Toscano Tumori, Lido di Camaiore, Italy 5 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy 6 Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria, Pisa, Italy 7 Medical Oncology Unit, Ospedale Sacro Cuore, Negrar, Italy 8 Medical Oncolgy Unit, Ospedale Santa Maria della Misericordia, Urbino, Italy 9 ARC-NET Research Centre and Department of Pathology and Diagnostics, Azienda Ospedaliero-Universitaria, Verona, Italy 10 Lung Diseases Unit, Azienda Ospedaliero-Universitaria, Pisa, Italy Correspondence to: Romano Danesi, email: [email protected] Keywords: cell-free circulating tumor DNA, KRAS, EGFR, activating mutation, tyrosine kinase inhibitors Received: June 24, 2015 Accepted: December 29, 2015 Published: January 20, 2016 ABSTRACT Introduction: KRAS oncogene mutations ( MUT KRAS ) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR mutations ( MUT EGFR ). However, inhibition of EGFR may select resistant cells displaying alternative signaling, i.e., KRAS , or restoration of EGFR activity due to additional MUT EGFR , i.e., the c.2369C > T ( p.T790M EGFR ). Aim: The aim of this study was to investigate the appearance of MUT KRAS during EGFR-TKI treatment and their contribution to drug resistance. Methods: This study used cell-free circulating tumor DNA (cftDNA) to evaluate the appearance of codon 12 MUT KRAS and p.T790M EGFR mutations in 33 advanced NSCLC patients progressing after an EGFR-TKI. Results: p.T790M EGFR was detected in 11 (33.3%) patients, MUT KRAS at codon 12 in 3 (9.1%) while both p.T790M EGFR and MUT KRAS codon 12 were found in 13 (39.4%) patients. Six patients (18.2%) were KRAS wild-type ( WT KRAS ) and negative for p.T790M EGFR . In 8 subjects paired tumor re-biopsy/plasma samples were available; the percent concordance of tissue/plasma was 62.5% for p.T790M EGFR and 37.5% for MUT KRAS . The analysis of time to progression (TTP) and overall survival (OS) in WT KRAS vs. MUT KRAS were not statistically different, even if there was a better survival with WT KRAS vs. MUT KRAS , i.e., TTP 14.4 vs. 11.4 months ( p = 0.97) and OS 40.2 vs. 35.0 months ( p = 0.56), respectively. Conclusions: MUT KRAS could be an additional mechanism of escape from EGFR-TKI inhibition and cftDNA is a feasible approach to monitor the molecular development of drug resistance.
Source: Oncotarget
Authors: Marzia Del Re, Marcello Tiseo, Paola Bordi, Armida D’Incecco, Andrea Camerini, Iacopo Petrini, Maurizio Lucchesi, Alessandro Inno, Daniele Spada, Enrico Vasile, Valentina Citi, Giorgio Malpeli, Enrica Testa, Stefania Gori, Alfredo Falcone, Domenico Amoroso, Antonio Chella, Federico Cappuzzo, Andrea Ardizzoni, Aldo Scarpa, Romano Danesi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2256274387
